Occlutech's Atrial Septal Defect Closure Device approved in Japan

Occlutech, a leading innovator of implants to treat structural heart disease today announced that it has obtained Japanese MHW approval for its dedicated Atrial Septal Defect Closure Device. The device is a specifically designed implant indicated for the minimally invasive closure of Atrial Septal Defects, ASD.

Tor Peters, CEO of Occlutech Group, commented: "We are extremely pleased to be able to provide patients and cardiologists in Japan with this innovative product and expect our ASD occluder to significantly add and improve therapy options for this patient population. Our partnership with Japan Lifeline has been very productive and we are proud to be associated with this company and its dedicated employees. A special thanks goes to the opinion leading physicians in Japan who have encouraged and supported this process."

Keisuke Suzuki, President and CEO of Japan Lifeline, also made the following statement: "In 2005 we pioneered the introduction of the first ASD occuluder in Japan, and we have been contributing to the spread of ASD Occuluders as patient-friendly and minimally invasive medical devices. Although we suspended sales of ASD occuluders in 2011 due to Distribution Agreement expiration, we are reentering the structural heart disease treatment market by introducing Occlutech's excellent products.

Occlutech's ASD occluder consists of a flexible nitinol wire mesh with "shape-memory" properties. Occlutech's proprietary technology allows for the creation of products with unique properties regarding flexibility and adaptability. The implant will be available in different configurations and sizes to accommodate a broad range of defects. The Occlutech ASD implant allows fast, atraumatic, minimally invasive closure of these defects. ASD closure using implantable devices is an alternative to open heart surgery.

Source:

Occlutech International AB

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Ketogenic diet lowers mortality by 24% while maintaining heart health